Paden King, Ph.D.

Paden King, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
Molecular Imaging Branch


Dr. King is focused on the development of metal-based anticancer therapeutics. He will be applying his knowledge of inorganic chemistry in the lab to develop novel radiometal chelators and conjugates for cancer therapy.

Areas of Expertise

Metals Chemistry
Cancer Molecular Radiotherapy


Selected Recent Publications

Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes

Marker SC, King AP, Granja S, Vaughn B, Woods JJ, Boros E, Wilson JJ.
Inorg Chem. 59(14): 10285-10303, 2020. [ Journal Article ]

Endoplasmic reticulum stress: an arising target for metal-based anticancer agents

King AP, Wilson JJ.
Chem Soc Rev. Epub ahead of print, 2020. [ Journal Article ]

Exploring Ovarian Cancer Cell Resistance to Rhenium Anticancer Complexes

Marker SC, King AP, Swanda RV, Vaughn B, Boros E, Qian SB, Wilson JJ.
Angew Chem Int Ed Engl. Epub ahead of print, 2020. [ Journal Article ]

Metal complexes as a promising source for new antibiotics

Frei A, Zuegg J, Elliott AG, Baker M, Braese S, Brown C, Chen F, G Dowson C, Dujardin G, Jung N, King AP, Mansour AM, Massi M, Moat J, Mohamed HA, Renfrew AK, Rutledge PJ, Sadler PJ, Todd MH, Willans CE, Wilson JJ, Cooper MA, Blaskovich MAT.
Chem Sci. 11(10): 2627-2639, 2020. [ Journal Article ]

In Vivo Anticancer Activity of a Rhenium(I) Tricarbonyl Complex

Konkankit CC, King AP, Knopf KM, Southard TL, Wilson JJ.
ACS Med Chem Lett. 10(5): 822-827, 2019. [ Journal Article ]